Sonoma Pharmaceuticals, Inc. (SNOA)

In the past six months, Sonoma Pharmaceuticals' stock has experienced several notable events and fluctuations. In August 2025, the company launched its HOCl-based diaper rash product in major U.S. retail channels, leading to a surge in premarket trading. The company also reported an 18% increase in total revenue year-over-year. In September 2025, the company participated in the Lytham Partners Fall 2025 Investor Conference and announced the FDA cosmetic product facility registration and listing of a Microcyn-based facial spray. In October 2025, Sonoma Pharmaceuticals and Medline Industries launched a new HOCl wound cleanser for U.S. hospitals. In November 2025, the company reported record quarterly revenue and Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel received the National Rosacea Society Seal of Acceptance. The company also exhibited at MEDICA 2025. In December 2025 and January 2026, the stock price showed daily fluctuations, with technical signals indicating a bearish outlook in the mid-term.

Information directly detailing the demand seasonality for Sonoma Pharmaceuticals' products and services is limited. Revenues in regions like Asia and Latin America can be "choppy" on a quarterly basis. There have been mentions of fluctuations in demand for over-the-counter animal health care products. The company's expansion into consumer-focused products might introduce new demand patterns that align with consumer purchasing habits.

Sonoma Pharmaceuticals, Inc. (SNOA) is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products. The company operates in the Health Technology sector, specifically within the Pharmaceuticals: Major industry, and focuses on wound care, animal health care, eye care, oral care, nasal care, podiatry, and dermatological conditions. Its product portfolio is based on its proprietary Microcyn® technology and includes dermatological products like Epicyn and Levicyn, wound care products like Microcyn, eye care products like Acuicyn, oral and nasal care products like Microdacyn60, animal health care products like MicrocynAH, and disinfectants like Nanocyn.

Sonoma Pharmaceuticals has a global presence, selling its products directly or through partners in over 55 countries. The company is headquartered in Boulder, Colorado, with manufacturing in Jalisco, Mexico, and European marketing and sales in Roermond, Netherlands. Its operations span the United States, Latin America, Europe, and Asia.

Sonoma Pharmaceuticals has enhanced its brand reputation through product recognition and regulatory compliance. Reliefacyn Advanced received the National Rosacea Society Seal of Acceptance. The company registered its manufacturing facility and listed a Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act. The launch of a new HOCl wound cleanser with Medline Industries and expansion into major U.S. retail channels also solidify its reputation.

Sonoma Pharmaceuticals is primarily owned by insiders and institutional shareholders. Insiders hold a significant portion of the company, while institutional shareholders own a smaller percentage. Robert Burlingame is the largest individual shareholder. Major institutional shareholders include Vanguard Group Inc and Geode Capital Management, Llc. Insider sentiment is considered positive, with multiple insiders buying shares over the last year.